Amneal and apiject to expand sterile and blow-fill-seal (bfs) capabilities for advanced pharmaceutical manufacturing in the u.s.

-adds bfs platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -expands amneal's extensive domestic pharmaceutical manufacturing footprint bridgewater, n.j., may 08, 2025 (globe newswire) -- amneal pharmaceuticals, inc. (nasdaq: amrx) (“amneal” or the “company”), an american biopharmaceutical company, and apiject systems, corp. (“apiject”), a medical technology company focused on advanced drug delivery, today announced a strategic collaboration to expand domestic production of apiject's bfs-based injectable platform at amneal's brookhaven, ny facility.
AMRX Ratings Summary
AMRX Quant Ranking